Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1998 Dec;52(12):775–785. doi: 10.1136/jech.52.12.775

Combined oral contraceptives, smoking, and cardiovascular risk

T M Farley, O Meirik, C L Chang, N R Poulter
PMCID: PMC1756661  PMID: 10396518

Abstract

STUDY OBJECTIVE: To assess age specific incidence and mortality of stroke, acute myocardial infarction (AMI), and idiopathic venous thromboembolism (VTE) associated with use of modern low dose combined oral contraceptives (OCs) and the interaction with smoking. DESIGN: Hospital-based case-control study. SETTING: Hospitals in Oxford region in the United Kingdom, which covered a defined population, during the period 1989-1993. METHODS: Relative risk estimates from the WHO Collaborative Study and observed incidence rates from the Oxford region were used to estimate age specific incidence of each disease among women without cardiovascular risk factors and model total cardiovascular incidence and mortality. RESULTS: Among women who did not use OCs, smoke nor had any other cardiovascular risk factors, total incidence of stroke and AMI were less than 2 events per 100,000 woman years in those aged 20-24 years and rose exponentially with age to 8 events per 100,000 among women aged 40-44 years. Incidence of idiopathic VTE among women who did not use OCs rose linearly with age (from 3.3 per 100,000 at ages 20-24 years to 5.8 per 100,000 at ages 40- 44 years). The increased risk of idiopathic VTE associated with OC use among non-smokers constituted over 90% of all cardiovascular events for women aged 20-24 years and more than 60% in those aged 40-44 years. Fatal cardiovascular events were dominated by haemorrhagic stroke and AMI, and among OC users who smoked these two diseases accounted for 80% of cardiovascular deaths among women aged 20-24 years, rising to 97% among those aged 40-44 years. Cardiovascular mortality associated with smoking was greater than that associated with OC use at all ages. Attributable risk associated with OC use was 1 death per 370,000 users annually among women aged 20-24 years, 1 per 170,000 at ages 30-34 years, and 1 per 37,000 at ages 40-44 years. Among smokers, the cardiovascular mortality attributable to OC use was estimated to be about 1 per 100,000 users annually among women aged less than 35 years, and about 1 per 10,000 users annually among those above the age of 35 years. CONCLUSION: The incidence of fatal cardiovascular events among women aged less than 35 years is low. The VTE risk associated with OC use is the largest contributor to OC induced adverse effects. The potentially avoidable excess VTE risk associated with the newer progestogens desogestrel and gestodene would account for a substantial proportion of total cardiovascular morbidity in this age group. For women over age 35 years the absolute risks associated with OC use and smoking are greater because of the steeply rising incidence of arterial diseases. The combination of smoking and OC use among such women is associated with particularly increased risks. Any potential reduction in AMI or stroke risk with use of third generation OCs would be a more important consideration among older compared with younger women, particularly if they smoke. However, the mortality associated with smoking is far greater than that associated with OC use (of any type) at all ages.

 

Full Text

The Full Text of this article is available as a PDF (155.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloemenkamp K. W., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 Dec 16;346(8990):1593–1596. doi: 10.1016/s0140-6736(95)91929-5. [DOI] [PubMed] [Google Scholar]
  2. Bonita R., Beaglehole R., North J. D. Event, incidence and case fatality rates of cerebrovascular disease in Auckland, New Zealand. Am J Epidemiol. 1984 Aug;120(2):236–243. doi: 10.1093/oxfordjournals.aje.a113885. [DOI] [PubMed] [Google Scholar]
  3. Farley T. M., Collins J., Schlesselman J. J. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception. 1998 Mar;57(3):211–230. doi: 10.1016/s0010-7824(98)00019-5. [DOI] [PubMed] [Google Scholar]
  4. Farmer R. D., Lawrenson R. A., Thompson C. R., Kennedy J. G., Hambleton I. R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997 Jan 11;349(9045):83–88. doi: 10.1016/s0140-6736(96)07496-x. [DOI] [PubMed] [Google Scholar]
  5. Jick H., Jick S. S., Gurewich V., Myers M. W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16;346(8990):1589–1593. doi: 10.1016/s0140-6736(95)91928-7. [DOI] [PubMed] [Google Scholar]
  6. Lewis M. A., Heinemann L. A., Spitzer W. O., MacRae K. D., Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception. 1997 Sep;56(3):129–140. doi: 10.1016/s0010-7824(97)00118-2. [DOI] [PubMed] [Google Scholar]
  7. Normand S. T., Glickman M. E., Sharma R. G., McNeil B. J. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. JAMA. 1996 May 1;275(17):1322–1328. [PubMed] [Google Scholar]
  8. Petitti D. B., Sidney S., Bernstein A., Wolf S., Quesenberry C., Ziel H. K. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996 Jul 4;335(1):8–15. doi: 10.1056/NEJM199607043350102. [DOI] [PubMed] [Google Scholar]
  9. Petitti D. B., Sidney S., Quesenberry C. P., Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke. 1997 Feb;28(2):280–283. doi: 10.1161/01.str.28.2.280. [DOI] [PubMed] [Google Scholar]
  10. Poulter N. R., Chang C. L., Farley T. M., Marmot M. G. Reliability of data from proxy respondents in an international case-control study of cardiovascular disease and oral contraceptives. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. J Epidemiol Community Health. 1996 Dec;50(6):674–680. doi: 10.1136/jech.50.6.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  12. Ridker P. M., Miletich J. P., Hennekens C. H., Buring J. E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997 Apr 23;277(16):1305–1307. [PubMed] [Google Scholar]
  13. Rosing J., Tans G., Nicolaes G. A., Thomassen M. C., van Oerle R., van der Ploeg P. M., Heijnen P., Hamulyak K., Hemker H. C. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997 Apr;97(1):233–238. doi: 10.1046/j.1365-2141.1997.192707.x. [DOI] [PubMed] [Google Scholar]
  14. Schwartz S. M., Siscovick D. S., Longstreth W. T., Jr, Psaty B. M., Beverly R. K., Raghunathan T. E., Lin D., Koepsell T. D. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med. 1997 Oct 15;127(8 Pt 1):596–603. doi: 10.7326/0003-4819-127-8_part_1-199710150-00003. [DOI] [PubMed] [Google Scholar]
  15. Schwingl P. J., Shelton J. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contraception. 1997 Mar;55(3):125–129. doi: 10.1016/s0010-7824(97)00026-7. [DOI] [PubMed] [Google Scholar]
  16. Sidney S., Petitti D. B., Quesenberry C. P., Jr, Klatsky A. L., Ziel H. K., Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol. 1996 Dec;88(6):939–944. doi: 10.1016/s0029-7844(96)00351-1. [DOI] [PubMed] [Google Scholar]
  17. Sonke G. S., Stewart A. W., Beaglehole R., Jackson R., White H. D. Comparison of case fatality in smokers and non-smokers after acute cardiac event. BMJ. 1997 Oct 18;315(7114):992–993. doi: 10.1136/bmj.315.7114.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Spitzer W. O., Lewis M. A., Heinemann L. A., Thorogood M., MacRae K. D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996 Jan 13;312(7023):83–88. doi: 10.1136/bmj.312.7023.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stadel B. V. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med. 1981 Sep 10;305(11):612–618. doi: 10.1056/NEJM198109103051104. [DOI] [PubMed] [Google Scholar]
  20. Thorogood M., Mann J., Murphy M., Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol. 1992 Jul 1;136(1):35–45. doi: 10.1093/oxfordjournals.aje.a116418. [DOI] [PubMed] [Google Scholar]
  21. Thorvaldsen P., Asplund K., Kuulasmaa K., Rajakangas A. M., Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke. 1995 Mar;26(3):361–367. doi: 10.1161/01.str.26.3.361. [DOI] [PubMed] [Google Scholar]
  22. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A. M., Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583–612. doi: 10.1161/01.cir.90.1.583. [DOI] [PubMed] [Google Scholar]
  23. Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 Nov 26;344(8935):1453–1457. doi: 10.1016/s0140-6736(94)90286-0. [DOI] [PubMed] [Google Scholar]
  24. Westhoff C. Factor V Leiden and third-generation oral contraceptives. Lancet. 1996 Feb 10;347(8998):396–397. doi: 10.1016/s0140-6736(96)90573-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES